Systems and methods for inducing epigenetic changes in cells and tissues of the eye and orbit
By using wearable devices for electromagnetic stimulation, the epigenetic changes of the retina are induced, which solves the problem of difficult to prevent or delay the progress of retinal diseases in the prior art, and has achieved effective impact on retinal neuroprotection, delayed the degenerative retinal disease. progress.
Patent Information
- Application Number
- CN202080075919.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-10-28
- Filing Date
- 2020-10-28
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2040-10-28
AI Technical Summary
Existing treatment methods for retinal diseases are difficult to effectively prevent or delay neuronal loss, especially blinding disorders such as retinal pigmentation, age-related macular degeneration and glaucoma, and lack effective means to slow disease progression in the early stage.
Using wearable devices, signals are emitted through external radio frequency (RF) coils and received by internal RF coils, combined with multiple stimulation electrodes for electromagnetic stimulation, inducing epigenetic changes in cells or tissues in the inner or adjacent areas of the eye, thereby affecting neuroprotection. and gene expression slows the progression of retinal degenerative diseases.
This method can slow neuronal loss in the early stages of retinal disease, delay disease progression, and combine it with medication or surgery as an auxiliary means in the late stage to provide a more reliable and repeatable neuroprotective effect.
Smart Images

Figure CN114616025B_ABST
Abstract
Description
[0001] Cross-references
[0002] This application claims the benefit of and priority to U.S. Provisional Application Serial No. 62 / 927038, filed on October 28, 2019, entitled “SYSTEMS AND METHODS FOR INDUCTING EPIGENETIC CHANGES IN CELLS AND TISSUE OF THE EYE AND ORBIT,” the contents of which are incorporated herein by reference in their entirety.
[0003] Government licensing rights
[0004] This invention was made with U.S. Government support under Contract No. 1,933,394 awarded by the National Science Foundation. The U.S. Government has certain rights in this invention. Background Art 1. Technical Field
[0006] The present description relates to systems and methods for inducing changes in the eye or an area adjacent to the eye.
[0007] 2. Description of Related Technology
[0008] Retinal blindness, such as retinitis pigmentosa (RP), age-related macular degeneration (AMD) and glaucoma (POAG) are multi-stage conditions characterized by the ongoing death of neurons (loss of photoreceptors in RP and AMD and loss of ganglion cells in POAG). Neuronal rewiring, reprogramming and migration can be manifested in the early stages of these conditions. Many mechanisms have been identified to explain why neuronal death occurs in these different retinal blinding disorders (e.g., genetic mutations in RP, abnormal lipid metabolism and inflammation in AMD, and high intraocular pressure in POAG, etc.). Although there are treatments to improve these conditions, there is no cure for many afflicted people. Therefore, there is a need to improve the treatment of these conditions. Summary of the invention
[0009] The present invention describes a system for causing changes in cells or tissues in or adjacent to an eye. The system includes an external RF coil configured to transmit RF (radio frequency) signals. The system also includes a wearable device configured to be removably disposed on the eye, the wearable device including a plurality of internal RF coils configured to receive RF signals from the external RF coil and a plurality of stimulation electrodes configured to induce changes in cells or tissues in or adjacent to the eye by electromagnetically stimulating a portion of the eye or an area adjacent to the eye.
[0010] The present invention also describes a method for causing changes in cells or tissues in or adjacent to an eye. The method includes transmitting an RF signal through an external RF coil. The method also includes receiving the RF signal from the external RF coil through a plurality of internal RF coils of a wearable device removably disposed on the eye. The method also includes stimulating the eye or an area adjacent to the eye through a plurality of stimulation electrodes, thereby causing changes in cells or tissues in or adjacent to the eye.
[0011] The present invention also describes a wearable device having an outer surface and an inner surface, the inner surface being configured to removably contact an eye of a user. The wearable device also includes a plurality of stimulation electrodes configured to electromagnetically stimulate the eye or an area adjacent to the eye, thereby causing cell or tissue changes in or near the eye. BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Other systems, methods, features and advantages of the present invention will be apparent to those skilled in the art after examining the following drawings and detailed description. The components shown in the drawings are not necessarily drawn to scale and may be exaggerated to better illustrate important features of the present invention.
[0013] According to various embodiments of the present invention, Figure 1 An overview of the process of the system is illustrated.
[0014] According to various embodiments of the present invention, Figure 2A A system for inducing changes in the eye or surrounding / adjacent areas is illustrated.
[0015] According to various embodiments of the present invention, Figure 2B The diagram shows Figure 2A A wearable device used in the system.
[0016] According to various embodiments of the present invention, Figure 2C The diagram illustrates stimulation electrodes of the wearable device.
[0017] According to various embodiments of the present invention, Figure 3 A portion of an eye that can be treated by the system is illustrated.
[0018] According to various embodiments of the present invention, Figure 4 The external RF coil located on the device is shown.
[0019] According to various embodiments of the present invention, Figures 5A-5C Several embodiments of the system are illustrated.
[0020] According to various embodiments of the present invention, Fig. 6A The process of inducing change using the system is illustrated.
[0021] According to various embodiments of the present invention, Figure 6B The process of validating epigenetic changes induced by the system is illustrated.
[0022] According to various embodiments of the present invention, Figures 7A-7L The diagram shows a circuit schematic of the system and the characteristics of these components.
[0023] According to various embodiments of the present invention, Figures 8A-8D The diagram shows a circuit schematic of the system and the characteristics of these components.
[0024] According to various embodiments of the present invention, Figures 9A-9B A simulation of the system is illustrated.
[0025] According to various embodiments of the present invention, Fig.10 Shown is a heatmap of unsupervised hierarchical clustering of the most significant differentially methylated regions (DMRs).
[0026] According to various embodiments of the present invention, Fig.11 A scatter plot showing the correlation between methylation beta values derived from whole genome methylation sequencing (WGBS) and targeted bisulfite sequencing is illustrated.
[0027] According to various embodiments of the present invention, Fig.12 Shown are the expression levels of selected genes measured by quantitative reverse transcription polymerase chain reaction (qRT-PCR) in the retinas of rats with retinal degeneration at various time points after transcorneal electrical stimulation (TES).
[0028] According to an embodiment of the present invention, Figures 13A-13B The differentially methylated regions (DMRs) identified as being most significantly altered following electrical stimulation are shown. DETAILED DESCRIPTION
[0029] While the field of classical epigenetics has been extensively studied, neuroepigenetics (the study of epigenetics of postmitotic neurons) is a relatively new and emerging field of research. In addition, data on retinal epigenetics, which is considered a product of the central nervous system (CNS), is particularly scarce. Electrical stimulation of the retina or cultured Muller cells can result in transcriptomic changes that reflect neuroprotective changes, including downregulation of pro-apoptotic genes such as Bax and upregulation of pro-survival genes such as brain-derived neurotrophic factor (bdnf). The systems and methods described herein demonstrate for the first time that controlled, non-invasive electrical stimulation can result in epigenetic changes in the retina and affect neuroprotection. The systems and methods described herein allow retinal neuroprotection to be systematized and therefore more reliable and reproducible.
[0030] Thus, the systems and methods described herein are based on the neural epigenetic and chromatin remodeling of the retina induced by controlled electrical stimulation, which is a key molecular determinant of neuroprotection. This is crucial for the treatment of retinal degenerative diseases, such as Figure 1 As shown. The systems and methods described herein use a non-invasive wearable device to control electrical stimulation to induce epigenetic changes in the eye, thereby slowing the progression of neurodegeneration. In some embodiments, the wearable device is a soft, ring-shaped contact lens with coils and electrodes that is worn at night and may be referred to herein as an "e-lens".
[0031] The pathological mechanisms of prevalent retinal diseases, such as photoreceptor degenerations such as retinitis pigmentosa (RP) (and age-related macular degeneration (AMD) or primary open-angle glaucoma (POAG)), are better understood. Nevertheless, since, for example, more than 100 mutations can cause RP, curing families with this mutation has been a difficult task, except for the success of a rare one-time gene therapy for Leber congenital amaurosis (RPE65 mutation). Similarly, as glaucoma progresses, intraocular pressure control becomes more difficult and neuroprotection is required.
[0032] Previous utilization of electromagnetic stimulation of the retina has been limited to rehabilitation devices, typically used to bypass damaged neurons to restore partial vision in patients with near-total blindness. The systems and methods described herein introduce a different approach through a paradigm shift to prevent or delay neuronal loss experienced in incurable diseases such as RP, AMD, and POAG. Controlled electromagnetic fields can modulate functional and morphological neural changes through transcriptional regulation of gene expression that exploits chromatin packaging and epigenome remodeling. This approach could be used both early in retinal disease to slow progression and in later stages of the disease to complement medical and surgical treatments. It is important to note that the form of electrical stimulation used herein is very different and is not the type used in neuroprosthetics, which uses electrical stimulation to bypass damaged photoreceptors and activate remaining retinal neurons to restore visual function.
[0033] Transcorneal electrical stimulation (TES) can reduce photoreceptor mortality and slow the progression of retinal degenerative diseases. Other noninvasive approaches may have multiple effects on the retina, from promoting survival of axotomized retinal ganglion cells to rescuing photoreceptors. However, the causes of these effects are poorly described, and understanding of the underlying mechanisms is limited.
[0034] Figure 2AA system 200 for transcorneal electrical stimulation (TES) is illustrated. The system 200 includes a wearable device 202 configured to be removably disposed on an eye 203. That is, the wearable device 202 can be placed on and removed from the eye 203. The wearable device 202 can be similar to contact lenses in material, shape, and size. In some embodiments, a hole 207 is provided in the center of the wearable device 202 to allow corneal oxygenation. The hole 207 can also provide openings for the cornea, iris, and pupil (among other parts of the eye 203), enabling the user to see through the wearable device 202.
[0035] The wearable device 202 includes a plurality of internal radio frequency (RF) coils 204 connected to a plurality of stimulation electrodes 206. The wearable device 202 is also connected to the internal RF coils 204. The stimulation electrodes may be one or more capacitors and diodes 210.
[0036] The stimulation electrodes 206 are designed to maximize current flow in the retina without covering or damaging the cornea, as determined by computational simulations described herein.
[0037] The internal RF coil 204 is configured to receive energy inductively from the external RF coil 208. That is, the external RF coil 208 transmits an RF signal to the internal RF coil 204, and the internal RF coil 204 receives the RF signal. The energy received from the external RF coil 208 is provided to the stimulation electrodes to stimulate various parts of the eye 203.
[0038] There can be any number of stimulation electrodes 206 located at different locations on the wearable device 202. The stimulation electrodes 206 can have any shape suitable for treating the eye 203. There can also be any number of internal RF coils 204 with any number of turns. The exact number of internal RF coils 204 and stimulation electrodes 206 can vary based on the application of the system 200 and / or the size or dimensions of the user's eye 203. Similarly, the exact number of external RF coils 208 can also vary.
[0039] Figure 2BThe wearable device 202 is illustrated without the internal RF coil 204. The wearable device 202 has an outer surface 212 and an inner surface 214. The inner surface 214 is configured to contact the user's eye 203. The outer surface 212 is opposite to the inner surface 214 and the outer surface 212 faces the external RF coil 208. The wearable device 202 may also include a plurality of grooves 216 for receiving and accommodating the internal RF coil 204. The plurality of grooves 216 may be located on the outer surface 212 or the inner surface 214. In some embodiments, the plurality of grooves 216 are channels formed in the wearable device 202, and the internal RF coil 204 is embedded between the outer surface 212 and the inner surface 214 of the wearable device 202.
[0040] The stimulation electrode 206 and capacitor and diode 210 may be located on the outer surface 212 or the inner surface 214 of the wearable device 202, or in some embodiments, may be embedded in the material of the wearable device 202 so that they are located between the outer surface 212 and the inner surface 214. The stimulation electrode 206 located on the eye 203 helps to effectively reduce impedance compared to a system where the stimulation electrode is located outside the eye and the eyelid is located between the eye and the stimulation electrode. In a system where the eyelid separates the eye and the stimulation electrode, the eyelid and other parts of the user may introduce impedance to the system, thereby reducing efficiency and efficacy.
[0041] Figure 2C An example layout of stimulation electrodes 206 (e.g., negative electrode 206A, positive electrode 206B, ground electrode 206C) of the wearable device 202 is illustrated. There may be an arc-shaped ground electrode 206C located in the upper half of the wearable device 202. There may also be a negative electrode 206A located in the lower right quadrant of the wearable device 202 and a positive electrode 206B located in the lower left quadrant of the wearable device 202. The location of the stimulation electrodes 206 may result in stimulation being focused on a specific location 218 of the eye.
[0042] Figure 2C The illustrated embodiment is an example embodiment of the location and shape of stimulation electrodes 206 for focusing stimulation at location 218, other embodiments for focusing stimulation at other locations are possible.
[0043] There may be a link between changes in chromatin and epigenomic dynamics and electromagnetic field exposure, particularly when applied to the retina. Although genetic and epigenetic changes are involved in the initiation and progression of retinal degeneration, there are no epigenetic-based therapies to slow or stop the continued progression of degenerative changes in the retina at the level of photoreceptors or ganglion cells. The systems and methods described herein are a completely different approach to using electromagnetic fields and non-invasively inducing epigenetic changes that have neuroprotective effects (i.e., using a custom lens with a biocompatible coil and electrodes to induce epigenetic changes to protect retinal neurons in animal models of photoreceptor and ganglion cell degeneration in animal models). This approach can be used both for early-stage diseases such as RP, AMD, and POAG, and as an adjunct to late-stage retinal diseases in combination with drugs, devices, or surgery. For example, the wearable device 202 can be worn overnight because it does not completely cover the cornea and therefore does not interfere with corneal oxygenation. Overnight use makes it easy to comply because it does not interfere with daytime activities such as reading.
[0044] The systems and methods described herein can also be used for other neurodegenerative diseases and neural injuries, such as stroke or closed head injury. The benefits of the systems and methods are that they can also be used for diseases in which known epigenetic changes are involved in their progression, such as cancer. For example, early glioblastoma (a type of brain cancer) can be delayed in progression, and neurons around the cancer can also be protected from cell death.
[0045] Figure 3 The system 200 is illustrated as being able to stimulate the eye 203 and various areas of the eye. In particular, the retina 302 and optic nerve 304 can be stimulated to treat retinal blindness, such as retinitis pigmentosa (RP), age-related macular degeneration (AMD), and glaucoma (POAG). The ciliary body 306 can be stimulated to treat or delay presbyopia. A portion of the eye or within the eye can be treated, as well as areas adjacent to the eye. The tear glands (not shown) that produce tears can also be stimulated to treat dry eyes. The corneal epithelium can also be treated.
[0046] Figure 4An example device that can accommodate an external RF coil 208 is illustrated. For example, the external RF coil 208 can be accommodated in a mask 402 or glasses 404. The system 200 can be used when the user is sleeping. Therefore, a mask 402 with an RF coil 208 at a position corresponding to the user's eyes can be used. Similarly, glasses 404 can be used when the user is not sleeping, wherein the RF coil 208 is located at a position corresponding to the user's eyes. The RF coil 208 can be within a sufficient distance from the internal RF coil 204 to inductively provide energy to the stimulation electrode 206 when the user wears the mask 402 or glasses 404. The device that accommodates the external RF coil 208 can contain a power supply or can be connected to a power supply to provide current to the external RF coil 208.
[0047] Figure 5A A system 500 is illustrated having a wearable device 202 and an external RF coil 208 as described herein. The wearable device 202 can have a stimulation electrode 206 connected to an internal RF coil 204 as described herein. The internal RF coil 204 can be inductively powered by the external RF coil 208. The internal RF coil 204 can power the stimulation electrode 206 to stimulate a portion of the eye as described herein.
[0048] Figure 5B A system 520 that does not include inductive energy transfer is illustrated. The wearable device 202 includes a stimulation electrode 206 and also includes an internal power source 502 configured to provide energy to the stimulation electrode 206. The internal power source 502 can be disposed on or within the wearable device 202. In some embodiments, the internal power source 502 is a battery. In some embodiments, the internal power source 502 is a device that generates electricity based on motion, such as a friction generator. Electricity can be generated based on the movement of the user, including movement of the eyes. In this way, the system 520 is an independent processing device. In an embodiment where the internal power source 502 is a power generation device, the internal power source 502 can also include an energy storage device, such as a battery.
[0049] Figure 5CThe system 540 that also does not include inductive energy transfer is illustrated. The wearable device 202 includes a stimulation electrode 206 connected to an external power source 504, and the external power source 504 is configured to provide energy to the stimulation electrode 206. In some embodiments, the external power source 504 is a battery. In some embodiments, the external power source 504 is a device based on solar power generation, such as a solar panel. In some embodiments, the external power source 504 is a device that generates electricity based on motion, such as a friction generator. Electricity can be generated based on the movement of the user. The external power source 504 can be located on a device worn by the user, such as glasses or a hat or an adhesive patch placed on the user's skin. In an embodiment where the external power source 504 is a power generation device, the external power source 504 can also include an energy storage device, such as a battery.
[0050] In some embodiments, an external mobile computing device such as a smartphone, laptop, or tablet can control the wearable device 202, including, for example, providing instructions for controlling the stimulation electrodes. The external mobile computing device can be communicatively connected to the wearable device 202 using a wired connection or a wireless connection, and can perform communication using appropriate hardware such as a transceiver and a corresponding communication protocol such as Bluetooth.
[0051] Fig. 6A A process 600 for causing changes in cells or tissues in or adjacent to an eye is illustrated. An external radio frequency (RF) coil (e.g., external RF coil 208) transmits an RF signal (step 602). Multiple internal RF coils (e.g., internal RF coil 204) receive RF signals from the external RF coils (step 604). The internal RF coils are located on a wearable device (e.g., wearable device 202), which is removably disposed on an eye (e.g., eye 203). Multiple stimulation electrodes (e.g., stimulation electrodes 206) stimulate the eye or an area adjacent to the eye of a patient / user, causing changes in cells or tissues in or adjacent to the eye (step 606). As used herein, "cells or tissues adjacent to the eye" refers to any cell or tissue adjacent to, around, near, adjacent to, or surrounding the eye, and "area adjacent to the eye of a patient or user" refers to any body area adjacent to, around, near, adjacent to, or surrounding the eye.
[0052] Figure 6B A process 620 for verifying epigenetic changes induced by the system described herein is illustrated. In particular, one or more steps of the process 600 may be performed using a computing device having a computer processor and a non-transitory memory storing instructions executed by the computer processor.
[0053] Differentially methylated regions (DMRs) are measured using whole genome bisulfite sequencing in response to electrical stimulation (step 622). DMRs are validated using targeted bisulfite amplicon high-throughput sequencing (step 624). Transcriptional changes are confirmed (step 626), and DMRs are used as biomarkers in response to electrical stimulation and for monitoring the duration of the effect at the molecular level (step 628).
[0054] With respect to the internal RF coil 204 and the external RF coil, various electrical components may be used. Traditionally, half-wave rectifiers are a popular solution for wireless passive electrodes. However, half-wave rectifier (HWR) solutions do not provide charge-balanced waveforms. That is, HWR is always single-phase in each cycle. Using a charge-balanced waveform is important to avoid unbalanced charge transfer through the eye tissue. The charge-balanced waveform for each cycle is biphasic.
[0055] The circuit 700 shown in FIG7 can be used in the systems and methods described herein. The circuit 700 includes a transmitter portion 702 and a receiver portion 704. The transmitter portion 702 can be used with the external RF coil 206, and the receiver portion 704 can be used with the internal RF coil 204. For a given load and input condition, the circuit 700 is able to deliver charge balance and a higher output voltage than a half-wave rectifier system. The output voltage across the load resistor is the node OUT p and OUT n The circuit 700 assumes that the load of the current stimulation system is in kΩ. In the HWR circuit, one end of the load resistor is grounded and the other end of the load resistor is switched to positive or negative value depending on the diode polarity. The grounded side of the load resistor is also connected to one end of the receiver coil to complete the circuit. However, unlike the HWR, the circuit 700 implements the load resistor (R) by generating a negative voltage without losing efficiency. load ) across the load. The voltage across the load is given by V(a) - V(b).
[0056] Receiving inductance L Receiver , D1, C s1 and C L1 At node OUTp, a HWR charge-balanced positive rectifier circuit is formed. Similarly, the receiving inductor L Receiver , D2, C s2 and C L2 At node OUT n A negative rectifier circuit is formed to balance the HWR charge. Normally, a series capacitor in series with a single HWR circuit would reduce the output voltage. However, in circuit 700, when the load voltage is tapped differentially, the effective output voltage increases. The load resistor is connected so that it acts as an RF blocker. Figure 7B-7EThe performance of circuit 700 is illustrated. The waveform can be adjusted by adjusting components such as capacitors.
[0057] In addition, further steps may be taken to increase the output voltage further than that provided by the circuit topology. The effect of these further steps is Figure 7F-7I The transmitted input signal may be a pulsed RF signal. Using a Type 3 RF signal results not only in a higher induced voltage but also in an asymmetric induction of the open circuit voltage of the secondary coil. This asymmetry in the induced voltage increases the load output voltage. The peak-to-peak voltage of all signals may be the same (e.g., 5V). The asymmetry caused by the Type 3 signal can be attributed to the differentiation nature of the induction process.
[0058] The circuit 700 can be further modified by adding a diode D3 as shown in FIG7 to increase the anode voltage without affecting the cathode voltage. The effect of the modified circuit on the load voltage and charge is shown in FIG. Figure 7K and 7L Reference Figure 7K and 7L In circuit A, there is no diode D3. Figure 7J The circuit, reference Figure 7K and 7L The circuit B is Figure 7J This modification also facilitates controlling the anode charge decay rate independently of the cathode charge decay rate. This is useful in adjusting the shape of the stimulation waveform without affecting the efficiency of the system. In existing single-phase half-wave rectifier and voltage doubler circuits, it is not possible to independently adjust the anode decay rate.
[0059] With C L1 and C L2 In comparison, it can be C s1 and C s2 Choose a larger capacitance value. A larger series capacitance value can result in higher load current and load voltage. This provides less resistance to the current flowing through the diode. Also, this results in fast charging and discharging of the cathode pulse.
[0060] The output voltage for a Type 3 RF voltage input can be increased by increasing the conduction of diode D2, i.e., the relative polarity of the coils shown in circuit 700. For example, replacing the 1N5819 diode with an MBR745 diode would increase the output voltage. In addition, with D2 and C s2 Connecting diodes and capacitors in parallel can increase the output voltage.
[0061] The output voltage and charge balance waveforms of HWR and circuit 700 are shown below. The two systems are compared under similar input waveforms, transmitter-receiver coils, and load conditions. The details of the simulation parameters are given in the table below. The output voltage of the proposed circuit is higher than that of HWR. In addition, unlike HWR, circuit 700 achieves charge balance.
[0062]
[0063]
[0064] The comparison of the output voltage and charge between the proposed system and HWR is shown in Figure 7H and 7I middle.
[0065] Fig. 8A The circuit 800 shown in FIG. 800 can be used in the systems and methods described herein. The circuit 800 includes a transmitter portion 802 and a receiver portion 804. The transmitter portion 802 can be used with the external RF coil 206, and the receiver portion 804 can be used with the internal RF coil 204.
[0066] Similar to circuit 700, circuit 800 is charge balanced. However, circuit 700 will produce different waveforms depending on the load resistance, which is the resistance from the eye. Therefore, different eyes and different states of the eye may result in different load resistances, and the shape of the waveform from receiver portion 704 may vary based on the eye.
[0067] In contrast, circuit 800 is load independent. That is, the same waveform shape is achieved from receiver portion 804 regardless of the load resistance from the user's eye. Figure 8B The waveform of the input voltage is shown in the figure. Figure 8C and 8D It is illustrated that the same waveform is achieved at the receiver portion 804 regardless of the load resistance, demonstrating the load independent capability of the circuit 800.
[0068] Shifting the focus to the effects of electrical stimulation, neurons communicate via electrical signals, which have been shown to induce neuroplasticity, including in the retina, and protect damaged nervous systems. While electrical stimulation of the eye has been shown to be effective, it is important to avoid stimulating other neurons, including those in the central nervous system. Therefore, a grounding system configuration was designed using COMSOL Multiphysics software that significantly limits the voltage distribution as well as the induced electric fields in the brain. Fig. 9A A human head model including the designed grounding system and stimulation electrodes is shown. Fig. 9BThe focused voltage distribution entering the eye is depicted. Initial simulation results demonstrate the potential for selective stimulation of the eye and further enhancement of the voltage gradient along the retina. This shows the use of designed ground geometry for maximum efficacy in stimulating the retina while avoiding inducing neural activity elsewhere in the body.
[0069] Preliminary calculations indicate that using a 12-turn coil with an inductance of 5 μH on an electronic lens sized to fit a rat eye (about 8 mm in diameter), an AC current of about 100 μA powered by a 1 A current using an external coil, is comparable to the current used in currently commercialized artificial retina systems and has been shown to be safe at very low frequencies. To further improve the coupling between the external coil and the lens coil, a solution directly applicable to the proposed geometry can be used. In some embodiments, the wireless lens is worn for a limited time each day (primarily at night), while the transmitting external coil is integrated into a wearable mask or similar device.
[0070] Chromatin is a compact and highly ordered hierarchical assembly of DNA and proteins that is intricately folded in three dimensions to form different levels of organization within the cell nucleus. Chromatin packing density has a non-monotonic effect on the probability of gene expression, increasing expression rates at chromatin packing densities below approximately 35% of the chromatin volume concentration and inhibiting expression at higher chromatin densities due to the competing effects of two consequences of molecular crowding, increased binding of transcriptional complexes and inhibition of spreading. Recent evidence suggests that chromatin packing scaling regulates both transcriptional diversity (the dynamic range of gene expression) and cell-to-cell variation in gene transcription. Chromatin packaging regulates the transcriptional access of cells to their genomic space and is expected to have an impact on a wide range of cellular processes (e.g., cell differentiation, plasticity, tissue regeneration, and many diseases including neurodegenerative diseases). Depending on its location in the genome, DNA methylation can also affect proximal chromatin structure and regulate gene expression, playing a key role in biological processes such as embryonic development, X chromosome inactivation, genomic imprinting, and chromosome stability. Therefore, determining the methylation status at single base resolution in the genome is an important step toward elucidating its role in regulating many cellular processes and its disruption in disease.
[0071] To begin to explore the extent to which DNA methylation changes can be altered in response to electrical stimulation in vivo, whole-genome bisulfite sequencing (WGBS) was performed on the retinas of three TES-treated and three sham-treated retinal degeneration (RCS) rats. WGBS is able to detect DNA methylation at single-base pair resolution. Treatment of DNA with sodium bisulfite can distinguish between methylated and unmethylated cytosines in CpG dinucleotides. Comparative epigenomics has shown that genome-wide patterns of DNA methylation at certain genomic elements are conserved among vertebrates, suggesting that the regulatory role of DNA methylation is also conserved between species. Briefly, genomic DNA was sheared, end-repaired, 3'-adenylated, and ligated to adapters. The adapter-ligated DNA was then treated with sodium bisulfite and PCR amplified to achieve the yield required for sequencing. Paired-end sequencing of the bisulfite-converted library was performed on the NovaSeq 6000 System. WGBS reads were aligned to the Rattus norvegicus RNOR6 genome assembly using the Bowtie2 alignment algorithm of the open-source Bismark Bisulfite Read Mapper.
[0072] Data analysis using the software package metilene identified 2996 statistically significant DNA methylation differences between TES and sham-treated retinas. Unsupervised cluster analysis of the most significant differentially methylated regions (DMRs) and associated genes precisely separated the control sham group from the electrical stimulation group ( Fig.10 ). To initially investigate the molecular mechanisms of electrical stimulation, genes associated with the most significant DMRs were submitted to the IPA core analysis software. Most relevantly, the most enriched disease categories with p-values less than 10-3 were associated with neurological disorders, including many hereditary and X-linked disorders. The most significantly hypermethylated genes associated with neurological disease progression were Kcnab2, Cnr, and Nfia ( Fig.10 ). Actin cytoskeleton and PDGF signaling were the most enriched canonical pathways, and cytoskeletal remodeling is important in multiple aspects of retinal development and neuronal function. In addition, hypomethylation of the prosurvival genes BDNF and PDGFA, which have previously been shown to be electrically induced, was identified. Other genes in the significant DMRs included hypermethylation of the retinal GTPase regulator gene (RPGR) and RPGRIPP1. Targeted bisulfite amplicon sequencing was performed for 18 of these DMRs to confirm DNA methylation changes in response to TES stimulation in an independent group of RCS rat retinas. Of these 18 DMRs, 9 showed good concordance between whole genome and targeted bisulfite sequencing runs, with a correlation of 0.725 ( Fig.11), validating the method for identifying DMR consistency after TES processing.
[0073] To begin to elucidate the functional consequences of the observed epigenetic dysregulation and provide a more direct link between differentially methylated genes with functional alterations and expression of target genes for neuroprotection, quantitative reverse transcription polymerase chain reaction (qRTPCR) was performed and assayed on 30 genes associated with DMRs in the retinas of independent TES (n=2) and sham-treated (n=2) RCS rats. To examine the persistence of the response over time, rat retinas were harvested on the same day after stimulation (days 1, 3, and 6). Gene expression was normalized to an internal reference gene (Gapdh), and expression was then normalized to sham-stimulated controls. RNA expression of the 30 genes associated with DMRs was plotted and analyzed by principal component analysis (PCA). Of the 30 genes, 27 (90%) genes were overexpressed n=19 or downregulated (n=8) by at least 20% ( n=19) at any time point. Fig.12 ). Three genes showed no changes in gene expression. PCA revealed three different expression potentials defined by the timing and duration of the expression changes compared to the sham control. There were 12 genes that showed rapid (days 0-1) induction immediately after TES treatment, but expression was transient and returned to control levels by days 3-6. This included genes associated with healthy retinal development, such as upregulation of Rpgr and Ablim123, and genes associated with cytoskeletal remodeling, such as upregulation of Sept9 and Mpp6, which have also been shown to be important in retinal regeneration in zebrafish24. Another group of seven genes showed rapid and sustained induction of expression until day 6. This group of genes included upregulation of Pdgfa and Slco5a1 ( Fig.11 ). Pdgfa is not only stimulated by electrical stimulation 3, but also attracts astrocytes and promotes cell survival. Slco5a1 is a gene with a known function in rod cell function.
[0074] A final set of eight genes were downregulated compared to controls, but the reduction in expression was delayed and not apparent until day 6 after TES. These included downregulation of genes known to promote angiogenesis and neovascularization, such as Fgf8 and Fech ( Fig.12 Abnormal neovascularization of parts of the eye driven by angiogenic factors has been implicated in several blinding eye diseases 27, and inhibition of these factors, including Fech28, is currently being explored as a potential therapeutic approach. In addition, pro-apoptotic genes such as Rassf129 ( Fig.11) was downregulated. Since genes related to cell proliferation and apoptosis were identified in both methylation and gene expression analyses, we explored the possibility that TES treatment could also inhibit retinal cell apoptosis. To achieve this, whole-eye sections from TES- or sham-treated rats were subjected to immunohistochemical (IHC) staining of cleaved caspase-3, a marker of apoptotic cells, at multiple time points after stimulation. Three different fields of view were examined per eye, and an average of 1353 cells were counted in all layers of the retina per eye. After day 6, the percentage of apoptotic cells found in control rats was 1.46%, while it was 0.89 in TES-treated rats (p value of 0.021).
[0075] Overall, these preliminary data provide compelling evidence that TES can induce changes at the epigenetic and chromatin levels ( Figure 10-12 ). Most importantly, the study showed that these changes translated into functional changes, with corresponding changes in gene expression that could be directly linked to retinal regeneration, increased cell survival and inhibition of apoptosis, cytoskeletal remodeling, and inhibition of neovascularization in a portion of the eye, supporting the notion that TES-induced neural epigenetic remodeling leads to retinal survival and regeneration. Thus, preliminary data suggest that TES triggers a cascade of beneficial molecular changes in the retina.
[0076] Figures 13A-13B Differentially methylated regions (DMRs) identified as being most significantly altered following electrical stimulation are illustrated, and these DMRs can be used as putative biomarkers of response. Figures 13A-13B The list is not an exclusive list.
[0077] The exemplary embodiments of the method / system have been disclosed in an illustrative manner. Therefore, the terms used throughout should be understood in a non-restrictive manner. Although minor modifications to the teachings herein will occur to those skilled in the art, it should be understood that it is intended to be limited to the patent scope guaranteed herein is all such embodiments that reasonably fall within the scope of the improvements in the art made in accordance with this article. Except according to the attached claims and their equivalents, the scope should not be limited.
Claims
1. A system for transcorneal electrical stimulation, comprising: an external radio frequency (RF) coil for transmitting an RF signal; and A wearable device is configured to be removably disposed on a user's eyes, the wearable device being a contact lens, and the wearable device comprising: The center has a hole that allows corneal oxygenation. a plurality of internal RF coils configured to receive RF signals from the external RF coils, and a plurality of stimulation electrodes configured to electromagnetically stimulate a portion of an eye or an area adjacent to an eye, causing a change in cells or tissue of the eye, or causing a change in cells or tissue adjacent to the eye; The stimulation electrode includes a ground electrode located in the upper half of the wearable device, a negative electrode located in the lower right quadrant of the wearable device, and a positive electrode located in the lower left quadrant of the wearable device. 2 . The system of claim 1 , further comprising one or more capacitors connected to the plurality of internal RF coils.
3. The system according to claim 1, wherein: The contact lens includes a plurality of recesses, and each of the plurality of internal RF coils is configured to be positioned in a corresponding recess of the plurality of recesses.
4. The system according to claim 1, wherein: The internal RF coil is made of metal or other conductive material.
5. The system of claim 1, wherein the charge-balanced waveform is used to stimulate a portion of an eye or an area adjacent to an eye.
6. The system according to claim 1, wherein: The external RF coil is integrated into a mask or eyeglass frame configured to be worn by a user.
7. The system of claim 1, wherein the area adjacent to the eye is a tear gland for treating dry eye.
8. The system of claim 1, wherein the portion of the eye is a retina and an optic nerve.
9. The system according to claim 1, characterized in that One part of the eye is the ciliary body.
10. A wearable device for transcorneal electrical stimulation, the wearable device being contact glasses, the wearable device comprising: The center has a hole that allows corneal oxygenation. an outer surface and an inner surface, the inner surface configured to removably contact an eye of a user; and a plurality of stimulation electrodes configured to induce changes in cells or tissues in or adjacent to the eye by electromagnetically stimulating a portion of the eye or an area adjacent to the eye; The stimulation electrode includes a ground electrode located in the upper half of the wearable device, a negative electrode located in the lower right quadrant of the wearable device, and a positive electrode located in the lower left quadrant of the wearable device. 11 . The wearable device of claim 10 , further comprising a plurality of internal RF coils configured to receive RF signals from the external RF coils.
12. The wearable device of claim 11, wherein the plurality of internal RF coils are located within grooves on the inner surface.
13. The wearable device of claim 10, wherein the plurality of stimulation electrodes are powered by a battery.
14. The wearable device according to claim 10, wherein: The plurality of stimulation electrodes are powered by a triboelectric generator.
Citation Information
Patent Citations
Design of high-density microelectrode array outer-layer artificial retina front-end system
CN101791259A
Retinal prosthesis
CN103370037A
Stimulating electrode structure of artificial retina and artificial retina
CN106334258A
Electrode system, device and method for the treatment of eye diseases, in particular dry eye
CN108290042A
Contact lens with an energy harvesting unit
KR1020160141586A
